comparemela.com

Latest Breaking News On - Menin inhibition - Page 1 : comparemela.com

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Amir fathiResistance profileMenin inhibitor ziftomenibAdults withAcute myeloid leukemiaNpm1 mutationsRelapsed refractory amlNovel therapyClinical trialSafety profileAdverse eventsDrug adverse eventMrd testingMinimal residual diseaseMenin inhibitorsMenin inhibition

Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

- 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) mutations; no discontinuations due to treatment-related adverse events.

United statesGhayas issaSharon klahreMichaela metzgerCompany on twitterSyndax pharmaceuticalsEuropean commissionDrug administrationExchange commissionAmerican society of hematologyInternational numberPrnewswire syndax pharmaceuticals incSyndax pharmaceuticals incAmerican societyAnnual meetingChief executive

Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting

/PRNewswire/ Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies,.

United statesBriggsw morrisonEytan steinStephanie leeBenjamin kolinskiMelissa forstCompany phaseSyndax pharmaceuticalsDrug administrationExchange commissionAmerican society of hematologySyndax pharmaceuticals incAmerican societyAnnual meetingChief executive officerPresentation details

vimarsana © 2020. All Rights Reserved.